ArticleCell metabolism2018
Inosine Monophosphate Dehydrogenase Dependence in a Subset of Small Cell Lung Cancers.
Open access · bronzeAbstract read
In one paragraph
Article in Cell metabolism, 2018. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 128 papers.
0numbers the graph read from it
0cells of the map it votes in
128citing papers in PubMed
8.2field-weighted citation impact, top 2% of its field
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
128 citing papers in PubMed, 197 citations in OpenAlex.
- Lung cancer metabolism: a dynamic and adaptive network.Cellular and molecular life sciences : CMLS · 2026Review
- PTEN-loss confers dependence on the guanylate synthesis enzyme IMPDH in T-cell acute lymphoblastic leukemia.EMBO molecular medicine · 2026Article
- GTP biosynthesis is a therapeutic vulnerability in Rac1-mutant melanoma.bioRxiv : the preprint server for biology · 2026Article
- Dietary Polyphenol Acteoside-Related Molecular Signatures in Clear Cell Renal Cell Carcinoma: Multi-Omics Profiling and Functional Validation of IMPDH1.Food science & nutrition · 2026Article
- Nucleotide Metabolism in Health and Disease.MedComm · 2026Review
- Small Cell Lung Cancer Establishes a Metabolic Autocrine Mechanism Through Active Extracellular ATP Transport.Cancer science · 2026Article
- ALDH1L2 induces resistance to chemotherapy in small cell lung cancer by inhibiting ferroptosis.Redox biology · 2026Article
- IMP metabolic mechanisms and IMPDH targeting strategies in tumor metabolic reprogramming and therapy (Review).International journal of molecular medicine · 2026Review
- The oncogenic control of nucleotide synthesis.Oncogenesis · 2026Review
- Small Cell Lung Cancer Classification: Unraveling Heterogeneity to Enable Personalized Treatments.Cancer research · 2026Review
- Metabolic adaptations in cancer progression.Physiological reviews · 2026Review
- PTEN-loss confers dependence on the guanylate synthesis enzyme IMPDH in T-cell acute lymphoblastic leukemia.bioRxiv : the preprint server for biology · 2025Article
- A Novel Allosteric Inhibitor Targeting IMPDH at Y233 Overcomes Resistance to Tyrosine Kinase Inhibitors in Lymphoma.Cancers · 2025Article
- Y12C mutation disrupts IMPDH cytoophidia and alters cancer metabolism.The FEBS journal · 2025Article
- IMPDH inhibition induces DNA replication stress and ATR sensitivity in Merkel cell carcinoma.iScience · 2025Article
- Challenges of small cell lung cancer heterogeneity and phenotypic plasticity.Nature reviews. Cancer · 2025Review
- IMPDH2's Central Role in Cellular Growth and Diseases: A Potential Therapeutic Target.Cell proliferation · 2025Review
- Molecular Subtypes and Targeted Therapeutic Strategies in Small Cell Lung Cancer: Advances, Challenges, and Future Perspectives.Molecules (Basel, Switzerland) · 2025Review
- Unveiling the powerhouse: ASCL1-driven small cell lung cancer is characterized by higher numbers of mitochondria and enhanced oxidative phosphorylation.Cancer & metabolism · 2025Article
- Emilia sonchifolia (L.) DC. inhibits the growth of Methicillin-Resistant Staphylococcus epidermidis by modulating its physiology through multiple mechanisms.Scientific reports · 2025Article
68 more citing papers are in PubMed but not listed here.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
19 authors at 5 institutions in 2 countries.
Fang HuangInstitute of Hematology, Union Hospital, Tongji Medical College, Huazhong University of Science and Technology, Wuhan, Hubei 430022, China; Children's Medical Center Research Institute, University of Texas Southwestern Medical Center, Dallas, TX 75390, USA.
Min NiChildren's Medical Center Research Institute, University of Texas Southwestern Medical Center, Dallas, TX 75390, USA.
Milind D ChalishazarDepartment of Oncological Sciences, University of Utah, Huntsman Cancer Institute, Salt Lake City, UT 84112, USA.
Kenneth E HuffmanHamon Center for Therapeutic Oncology Research, University of Texas Southwestern Medical Center, Dallas, TX 75390, USA.
Jiyeon KimChildren's Medical Center Research Institute, University of Texas Southwestern Medical Center, Dallas, TX 75390, USA.
Ling CaiChildren's Medical Center Research Institute, University of Texas Southwestern Medical Center, Dallas, TX 75390, USA; Department of Clinical Science, University of Texas Southwestern Medical Center, Dallas, TX 75390, USA.
Xiaolei ShiChildren's Medical Center Research Institute, University of Texas Southwestern Medical Center, Dallas, TX 75390, USA.
Feng CaiChildren's Medical Center Research Institute, University of Texas Southwestern Medical Center, Dallas, TX 75390, USA.
Lauren G ZachariasChildren's Medical Center Research Institute, University of Texas Southwestern Medical Center, Dallas, TX 75390, USA.
Abbie S IrelandDepartment of Oncological Sciences, University of Utah, Huntsman Cancer Institute, Salt Lake City, UT 84112, USA.
Kailong LiChildren's Medical Center Research Institute, University of Texas Southwestern Medical Center, Dallas, TX 75390, USA.
Wen GuChildren's Medical Center Research Institute, University of Texas Southwestern Medical Center, Dallas, TX 75390, USA.
Akash K KaushikChildren's Medical Center Research Institute, University of Texas Southwestern Medical Center, Dallas, TX 75390, USA.
Xin LiuChildren's Medical Center Research Institute, University of Texas Southwestern Medical Center, Dallas, TX 75390, USA.
Adi F GazdarHamon Center for Therapeutic Oncology Research, University of Texas Southwestern Medical Center, Dallas, TX 75390, USA.
Trudy G OliverDepartment of Oncological Sciences, University of Utah, Huntsman Cancer Institute, Salt Lake City, UT 84112, USA.
John D MinnaHamon Center for Therapeutic Oncology Research, University of Texas Southwestern Medical Center, Dallas, TX 75390, USA.
Zeping HuChildren's Medical Center Research Institute, University of Texas Southwestern Medical Center, Dallas, TX 75390, USA; School of Pharmaceutical Sciences, Tsinghua University, Beijing 100084, China. Electronic address: zeping_hu@mail.tsinghua.edu.cn.
Ralph J DeBerardinisChildren's Medical Center Research Institute, University of Texas Southwestern Medical Center, Dallas, TX 75390, USA; Department of Pediatrics and Eugene McDermott Center for Human Growth and Development, University of Texas Southwestern Medical Center, Dallas, TX 75390, USA. Electronic address: ralph.deberardinis@utsouthwestern.edu.
The University of Texas Southwestern Medical Center · USChildren's Medical Center · USHuntsman Cancer Institute · USUnion Hospital · CNUniversity of Utah · US
Funding
UNIVERSITY OF TEXAS--SPORE IN LUNG CANCERP50CA070907 · NCI · UT SOUTHWESTERN MEDICAL CENTER · PI GIBBONS, DON LYNN · 1996 to 2024
$57.4MCoordinating center for the NCI small cell lung cancer research consortiumU24CA213274 · NCI · SLOAN-KETTERING INST CAN RESEARCH · PI Lauren Averett Byers, JOHN D. MINNA · 2017 to 2026
$12.9MMetabolic Regulators of Tumor Growth and ProgressionR35CA220449 · NCI · UT SOUTHWESTERN MEDICAL CENTER · PI RALPH J DEBERARDINIS · 2017 to 2026
$9.4MDeveloping ASCL1 and NeuroD1 lineage oncogene targeted therapy for small cell lung cancerU01CA213338 · NCI · UT SOUTHWESTERN MEDICAL CENTER · PI MINNA, JOHN D. · 2017 to 2021
$3.0MIdentifying Mechanisms of Sox2-Driven Squamous Cell Lung CancerR01CA187457 · NCI · UNIVERSITY OF UTAH · PI OLIVER, TRUDY GALE · 2014 to 2018
$1.5MHoward Hughes Medical InstituteNCI NIH HHS P50 CA070907NCI NIH HHS R01 CA187457NCI NIH HHS R35 CA220449NCI NIH HHS U01 CA213338NCI NIH HHS U24 CA213274
Abstract
Small cell lung cancer (SCLC) is a rapidly lethal disease with few therapeutic options. We studied metabolic heterogeneity in SCLC to identify subtype-selective vulnerabilities. Metabolomics in SCLC cell lines identified two groups correlating with high or low expression of the Achaete-scute homolog-1 (ASCL1) transcription factor (ASCL1
Indexed as
AnimalsBasic Helix-Loop-Helix ProteinsCell Line, TumorGuanosineHeterograftsHumansIMP DehydrogenaseLung NeoplasmsMiceMice, KnockoutSmall Cell Lung CarcinomaAscl1 protein, mouseBasic Helix-Loop-Helix ProteinsGuanosineIMP DehydrogenaseIMPDH1, mouseIMPDH2, mouseIMPDHlung cancermetabolismmetabolomicstherapeutics
Identifiers
What OpenQuestion holds
Textmetadata
LicenceTDM
Read underepoch 390
Registered trials
None linked
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.